Alpha-type-1 Polarized Dendritic Cells

BIOLOGICAL3 trials

Sponsors

Roswell Park Cancer Institute

Conditions

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8HLA-A2 Positive Cells PresentMetastatic Triple-Negative Breast CarcinomaRefractory MelanomaStage II Fallopian Tube Cancer AJCC v8Stage II Ovarian Cancer AJCC v8Stage II Primary Peritoneal Cancer AJCC v8

Phase 1

Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

WithdrawnNCT03735589

Roswell Park Cancer InstituteStage IIA Fallopian Tube Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIA Primary Peritoneal Cancer AJCC v8 +31

Start: 2023-12-15End: 2025-12-01Updated: 2023-11-22

Phase 2

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

TerminatedNCT04093323

Roswell Park Cancer InstituteHLA-A2 Positive Cells Present, Refractory Melanoma

Start: 2024-11-13End: 2025-06-19Updated: 2026-02-25

Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer

WithdrawnNCT05539365

Roswell Park Cancer InstituteAnatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma +1

Start: 2025-02-01End: 2027-02-01Updated: 2025-01-29

Related Papers

Systemic Infusion of dsRNA (Rintatolimod) plus IFNa Selectively Enhances Intratumoral CTL Influx in Cancer Patients 2701

The Journal of Immunology2025-11-01

Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma

Journal for ImmunoTherapy of Cancer2021-11-0150 citations